Alemtuzumab therapy lowers circulating and cerebrospinal immunoglobulin levels in multiple sclerosis

Takeaway

  • Alemtuzumab therapy reduces immunoglobulin levels in the peripheral blood and cerebrospinal fluid of people with relapsing-remitting multiple sclerosis.

Why this matters

  • This study provides Class IV evidence that long-term treatment with alemtuzumab can reduce immunoglobulin levels in relapsing-remitting multiple sclerosis. Prophylactic anti-infectives may be required, particularly in those receiving more than two treatment courses of alemtuzumab. 

Want to read more?

Log in or sign up to access all Neurodiem content.

Already have an account? Log In

International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.